Author

Mona Mohsen

University of Bern - Cited by 2,040 - Vaccine development - cancer immunology - cancer immunotherapy - cancer vaccine

Biography

Dr Mona O. Mohsen is working as a Research Associate in the Department of biomedical research at the Universität Bern, Switzerland.  Her main research interest is cancer immunology/ immunotherapy/ vaccine development based on virus-like particles for cancer and infectious diseases.
Title
Cited by
Year
Emerging COVID-19 variants and their impact on SARS-CoV-2 diagnosis, therapeutics and vaccines
Q Fernandes, VP Inchakalody, M Merhi, S Mestiri, N Taib, ...Annals of medicine 54 (1), 524-540, 2022202
179
2022
On iron metabolism and its regulation
ACS Vogt, T Arsiwala, M Mohsen, M Vogel, V Manolova, MF BachmannInternational journal of molecular sciences 22 (9), 4591, 2021202
108
2021
Virus‐like particles for vaccination against cancer
MO Mohsen, DE Speiser, A Knuth, MF BachmannWiley Interdisciplinary Reviews: Nanomedicine and Nanobiotechnology 12 (1 …, 2020202
81
2020
In vitro data suggest that Indian delta variant B. 1.617 of SARS‐CoV‐2 escapes neutralization by both receptor affinity and immune evasion
G Augusto, MO Mohsen, S Zinkhan, X Liu, M Vogel, MF BachmannAllergy 77 (1), 111-117, 2022202
64
2022
The 3Ds in virus‐like particle based‐vaccines: “Design, Delivery and Dynamics”
MO Mohsen, G Augusto, MF BachmannImmunological reviews 296 (1), 155-168, 2020202
59
2020
Vaccination with nanoparticles combined with micro-adjuvants protects against cancer
MO Mohsen, MD Heath, G Cabral-Miranda, C Lipp, A Zeltins, M Sande, ...Journal for immunotherapy of cancer 7, 1-12, 2019201
52
2019
SARS-CoV-2 structural features may explain limited neutralizing-antibody responses
MF Bachmann, MO Mohsen, L Zha, M Vogel, DE Speisernpj Vaccines 6 (1), 2, 2021202
41
2021
Zika virus-derived E-DIII protein displayed on immunologically optimized VLPs induces neutralizing antibodies without causing enhancement of dengue virus infection
G Cabral-Miranda, SM Lim, MO Mohsen, IV Pobelov, ES Roesti, ...Vaccines 7 (3), 72, 2019201
39
2019
BNT162b2 mRNA COVID‐19 vaccine induces antibodies of broader cross‐reactivity than natural infection, but recognition of mutant viruses is up to 10‐fold reduced
X Chang, GS Augusto, X Liu, TM Kündig, M Vogel, MO Mohsen, ...Allergy 76 (9), 2895, 2021202
38
2021
Development of a vaccine against SARS-CoV-2 based on the receptor-binding domain displayed on virus-like particles
L Zha, X Chang, H Zhao, MO Mohsen, L Hong, Y Zhou, H Chen, X Liu, ...Vaccines 9 (4), 395, 2021202
29
2021
Virus-like particle vaccinology, from bench to bedside
MO Mohsen, MF BachmannCellular & molecular immunology 19 (9), 993-1011, 2022202
28
2022
A scalable and highly immunogenic virus‐like particle‐based vaccine against SARS‐CoV‐2
MO Mohsen, I Balke, S Zinkhan, V Zeltina, X Liu, X Chang, PS Krenger, ...Allergy 77 (1), 243-7, 2022202
25
2022
Vaccination against allergy: a paradigm shift?
MF Bachmann, MO Mohsen, MF Kramer, MD HeathTrends in molecular medicine 26 (4), 357-368, 2020202
24
2020
The impact of size on particle drainage dynamics and antibody response
S Zinkhan, A Ogrina, I Balke, G Reseviča, A Zeltins, S de Brot, C Lipp, ...Journal of controlled release 331, 296-308, 2021202
24
2021
Molecular definition of severe acute respiratory syndrome coronavirus 2 receptor‐binding domain mutations: Receptor affinity versus neutralization of receptor interaction
M Vogel, G Augusto, X Chang, X Liu, D Speiser, MO Mohsen, ...Allergy 77 (1), 143-149, 2022202
19
2022
Development of a COVID-19 vaccine based on the receptor binding domain displayed on virus-like particles
L Zha, H Zhao, MO Mohsen, L Hong, Y Zhou, Z Li, C Yao, L Guo, H Chen, ...BioRxiv, 2020.05. 06.079830, 2020202
18
2020
AP205 VLPs based on dimerized capsid proteins accommodate RBM domain of SARS-CoV-2 and serve as an attractive vaccine candidate
X Liu, X Chang, D Rothen, M Derveni, P Krenger, S Roongta, E Wright, ...Vaccines 9 (4), 403, 2021202
18
2021
Early transcriptional signature in dendritic cells and the induction of protective T cell responses upon immunization with VLPs containing TLR ligands—A role for CCL2
AC Gomes, MO Mohsen, JE Mueller, FMS Leoratti, G Cabral-Miranda, ...Frontiers in immunology 10, 1679, 2019201
15
2019
Shaping Modern Vaccines: Adjuvant Systems Using MicroCrystalline Tyrosine (MCT®)
MD Heath, MO Mohsen, PJ De Kam, TL Carreno Velazquez, SJ Hewings, ...Frontiers in immunology 11, 594911, 2020202
14
2020
Low‐affinity but high‐avidity interactions may offer an explanation for IgE‐mediated allergen cross‐reactivity
X Chang, L Zha, A Wallimann, MO Mohsen, P Krenger, X Liu, M Vogel, ...Allergy 76 (8), 2565-2574, 2021202
11
2021

Referred From: https://scholar.google.com/citations?user=ndhfo9oAAAAJ&hl=en

Cited by
Citations 2040
h-index 24
i10-index 37
Recommended Journals
Open Access Journals